Analysts Set Expectations for Quanterix Co.'s Q1 2025 Earnings (NASDAQ:QTRX)

Quanterix Co. (NASDAQ:QTRX - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Quanterix in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst P. Souda forecasts that the company will earn ($0.22) per share for the quarter. The consensus estimate for Quanterix's current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for Quanterix's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.23) EPS.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05). The company had revenue of $31.55 million during the quarter, compared to analyst estimates of $27.92 million. Quanterix had a negative return on equity of 9.15% and a negative net margin of 26.42%.

A number of other equities analysts have also weighed in on the stock. Scotiabank upped their target price on shares of Quanterix from $30.00 to $32.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 4th. Canaccord Genuity Group reduced their price objective on shares of Quanterix from $32.00 to $25.00 and set a "buy" rating for the company in a research note on Monday, April 29th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $30.60.

Quanterix Stock Performance

NASDAQ QTRX traded down $0.44 on Friday, reaching $16.68. The company had a trading volume of 498,376 shares, compared to its average volume of 365,747. The firm has a market capitalization of $637.96 million, a price-to-earnings ratio of -19.91 and a beta of 1.41. Quanterix has a 1-year low of $14.26 and a 1-year high of $29.70. The company's fifty day moving average is $21.23 and its 200-day moving average is $23.05.

Insider Activity

In other news, Director Laurie J. Olson sold 1,500 shares of the company's stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the sale, the director now directly owns 15,238 shares of the company's stock, valued at approximately $371,045.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Robeco Institutional Asset Management B.V. bought a new position in Quanterix in the 3rd quarter valued at about $67,000. AJOVista LLC bought a new position in shares of Quanterix during the fourth quarter worth approximately $81,000. DekaBank Deutsche Girozentrale bought a new position in shares of Quanterix during the third quarter worth approximately $125,000. Picton Mahoney Asset Management bought a new position in shares of Quanterix during the fourth quarter worth approximately $139,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Quanterix by 56.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,683 shares of the company's stock worth $209,000 after purchasing an additional 2,775 shares during the period. 86.48% of the stock is owned by institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.